PMID- 37223012
OWN - NLM
STAT- MEDLINE
DCOM- 20230526
LR  - 20231101
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Analysis of mRNA-miRNA-lncRNA differential expression in prediabetes/type 2 
      diabetes mellitus patients as potential players in insulin resistance.
PG  - 1131171
LID - 10.3389/fendo.2023.1131171 [doi]
LID - 1131171
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a major global health concern. 
      It usually develops gradually and is frequently preceded by undetectable 
      pre-diabetes mellitus (pre-DM) stage. The purpose of this study was to identify a 
      novel set of seven candidate genes associated with the pathogenesis of insulin 
      resistance (IR) and pre-DM, followed by their experimental validation in 
      patients' serum samples. METHODS: We used the bioinformatics tools and through a 
      two-step process, we first identified and verified two mRNA candidate genes 
      linked to insulin resistance molecular pathogenesis. Second, we identified a 
      non-coding RNAs related to the selected mRNAs and implicated in the insulin 
      resistance molecular pathways followed by pilot study for the RNA panel 
      differential expression in 66 patients with T2DM, 49 individuals with prediabetes 
      and 45 matched controls using real time PCR. RESULTS: The levels of expression of 
      TMEM173 and CHUK mRNAs, hsa-miR (-611, -5192, and -1976) miRNAs gradually 
      increased from the healthy control group to the prediabetic group, reaching their 
      maximum levels in the T2DM group (p <10-3), whereas the levels of expression of 
      RP4-605O3.4 and AC074117.2 lncRNAs declined gradually from the healthy control 
      group to the prediabetic group, reaching their lowest levels in the T2DM group (p 
      <10-3). TMEM173, CHUK mRNAs, hsa_miR (-611 & -1976) and RP4-605O3.4 lncRNA were 
      useful in distinguishing insulin resistant from insulin sensitive groups. miR_611 
      together with RP4-605O3.4 exhibited significant difference in good versus poor 
      glycemic control groups. DISCUSSION: The presented study provides an insight 
      about this RNA based STING/NOD/IR associated panel that could be used for 
      PreDM-T2DM diagnosis and also as a therapeutic target based on the differences of 
      its expression level in the pre-DM and T2DM stages.
CI  - Copyright (c) 2023 Ali, Kamel, Agwa, Hakeem, Meteini and Matboli.
FAU - Ali, Hebatalla Said
AU  - Ali HS
AD  - Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain 
      Shams University, Abbassia, Cairo, Egypt.
FAU - Kamel, Marwa Mostafa
AU  - Kamel MM
AD  - Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain 
      Shams University, Abbassia, Cairo, Egypt.
FAU - Agwa, Sara H A
AU  - Agwa SHA
AD  - Clinical Pathology, Medical Ain Shams Research Institute, Ain Shams University, 
      Cairo, Egypt.
FAU - Hakeem, Mohamed S Abdel
AU  - Hakeem MSA
AD  - Institute of Immunology, University of Pennsylvania, Philadelphia, PA, United 
      States.
FAU - Meteini, Mahmoud Shawky El
AU  - Meteini MSE
AD  - Department of General Surgery, The School of Medicine, University of Ain Shams, 
      Cairo, Egypt.
FAU - Matboli, Marwa
AU  - Matboli M
AD  - Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain 
      Shams University, Abbassia, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230508
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Insulin)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - *Prediabetic State/genetics
MH  - *Diabetes Mellitus, Type 2/genetics
MH  - *RNA, Long Noncoding/genetics
MH  - *Insulin Resistance/genetics
MH  - Pilot Projects
MH  - Insulin
MH  - RNA, Messenger/genetics
PMC - PMC10200895
OTO - NOTNLM
OT  - bioinformatics
OT  - biomarkers
OT  - insulin resistance
OT  - non-coding RNA
OT  - pre-diabetes
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/24 13:08
MHDA- 2023/05/26 06:42
PMCR- 2023/01/01
CRDT- 2023/05/24 11:40
PHST- 2022/12/24 00:00 [received]
PHST- 2023/04/10 00:00 [accepted]
PHST- 2023/05/26 06:42 [medline]
PHST- 2023/05/24 13:08 [pubmed]
PHST- 2023/05/24 11:40 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1131171 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 May 8;14:1131171. doi: 
      10.3389/fendo.2023.1131171. eCollection 2023.